# Major Recall Alert: Amoxivue (Amoxicillin) 500mg Capsules Recalled Due to Substandard API Content and Quality Issues
The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert regarding the recall of **Amoxivue (Amoxicillin) 500mg capsules** manufactured by **Sparsh Bio-Tech Pvt. Ltd.** Following safety inspections, it was discovered that this product is substandard due to a significantly **low Active Pharmaceutical Ingredient (API) content of 26.3%**, coupled with weight variation and an **infrared absorption spectrum** that fails to meet established quality specifications.
If you or someone you know uses **Amoxivue**, read on to understand the risks, what actions to take, and how to stay informed about this critical health alert.
---
## Why This Recall is Important
Amoxivue, an **antibiotic containing amoxicillin**, is commonly prescribed to treat bacterial infections in patients. However, the compromised quality of the product poses serious public health risks:
- **Ineffective Treatment**: With only **26.3% of the required API content**, the capsules are significantly weaker than standard amoxicillin. This reduces their effectiveness in fighting infections, potentially worsening the health condition of users.
- **Drug Resistance Concerns**: Substandard antibiotics can lead to **antibiotic resistance**, a growing global health crisis where bacteria evolve to withstand effective medications.
- **Possible Health Risks**: Manufacturing inconsistencies, such as **weight variation** and abnormalities in **infrared absorption spectrum**, further compromise the safety and efficacy of the medication.
NAFDAC’s recall notice is a necessary step to protect public health and prevent harm associated with this substandard product.
---
## Details of the Recall
Here are the key facts about the recall:
- **Product Name**: Amoxivue (Amoxicillin) 500mg Capsules
- **Manufacturer**: Sparsh Bio-Tech Pvt. Ltd.
- **Recall Reason**:
- API content significantly low at 26.3%.
- Weight variation and infrared absorption spectrum did not meet established standards.
- Product classified as substandard.
- **Safety Advisory Issued by**: NAFDAC
- **Date Announced**: Noted in official alert [here](https://nafdac.gov.ng/public-alert-no-024-2025-recall-of-amoxivue-amoxicillin-500mg-capsules-due-to-significantly-low-active-pharmaceutical-ingredient-api-content/).
Affected parties, including distributors and healthcare providers, are urged **not to distribute or administer** this product for patient use.
*Affected product image courtesy of NAFDAC.*
---
## What You Should Do
If you are in possession of Amoxivue (Amoxicillin) 500mg capsules, or if you are unsure whether your medication may be affected, take the following steps immediately:
1. **Stop Using the Product**: Do not consume this medication, as its substandard quality may jeopardize your health or delay recovery.
2. **Report Suspicious Products**: Consumers, distributors, and healthcare personnel are urged to report cases of substandard products via any of these official NAFDAC channels:
- **NAFDAC Hotlines**
- **Email**: [Contact NAFDAC](https://nafdac.gov.ng/contact-us/)
- **Online Platform**: Submit complaints using [NAFDAC’s official platform](https://nafdac.gov.ng)
3. **Consult a Healthcare Professional**: Discuss alternative treatment options with a licensed healthcare provider to ensure bacterial infections are treated effectively.
4. **Buy Medications From Trusted Sources**: Always obtain medical products from licensed pharmacies or trusted distributors to avoid unsafe or falsified products.
---
## Stay Safe – Get Instant Recall Alerts
This incident highlights the critical importance of staying informed about product recalls that directly impact public health. Protect yourself and your loved ones by staying updated with real-time alerts.
💡 **Download the NAFDAC Recall App Today** and get instant notifications when products like Amoxivue are recalled. Stay one step ahead in safeguarding your health—**download now!**
For more details about the Amoxivue recall, refer to the official public alert [here](https://nafdac.gov.ng/public-alert-no-024-2025-recall-of-amoxivue-amoxicillin-500mg-capsules-due-to-significantly-low-active-pharmaceutical-ingredient-api-content/).
---
By taking proactive measures in response to recalls like this, we can collectively combat the distribution and use of substandard medical products. Stay vigilant, report any suspicious products, and always consult healthcare professionals for safe medication alternatives.